Intellia, Cellex Team Up On New CAR-T Firm, Backed By Blackstone

Blackstone is providing $250m to combine Intellia’s gene editing and Cellex’s cell manufacturing capabilities in a new CAR-T company using Cellex subsidiary GEMoaB’s technology and pipeline as a foundation.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.
Blackstone is investing $250m in a new CAR-T firm using Intellia, Cellex technology

Gene-editing specialist Intellia Therapeutics, Inc. and cell manufacturing firm Cellex Inc said on 22 June that they are teaming up with the private equity group Blackstone Life Sciences to create a new company focused on the development of chimeric antigen receptor T-cell (CAR-T) therapies for hard-to-treat cancers and autoimmune diseases. Blackstone will serve as the sole investor, contributing $250m to the enterprise, while Intellia and Cellex will be equal one-third owners with the investment firm.

[Sidebar#SC065134]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.